



# PRECISIONARY

## REFERENCES FOR TUMOR

All of these **peer-reviewed publications** have used the Compresstome® for successful tissue slices. If you have any questions, please contact us:

[www.precisionary.com](http://www.precisionary.com)

E-mail: [info@precisionary.com](mailto:info@precisionary.com)

Phone: 617-683-0586

### References

1. Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, Richardson ET, Dillon D, Montero-Llopis P, Barroso-Sousa R, Forman J, Shukla SA, Tolaney SM, Mittendorf EA, von Andrian UH, Wucherpennig KW, Hemberg M, Agudo J. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. *Cell*. 2022 May 12;185(10):1694-1708.e19. Epub 2022 Apr 20. PMID: 35447074.
2. Baldominos P, Barreiro O, von Andrian U, Sirera R, Montero-Llopis P, Agudo J. Protocol to isolate live single cells while retaining spatial information by combining cell photolabeling and FACS. *STAR Protoc*. 2022 Oct 28;3(4):101795. PMID: 36325581; PMCID: PMC9619724.
3. Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. *Nat Med*. 2018 Aug;24(8):1178-1191. Epub 2018 Jun 25. PMID: 29942093; PMCID: PMC6475503.
4. Ben-Hamo R, Jacob Berger A, Gavert N, Miller M, Pines G, Oren R, Pikarsky E, Benes CH, Neuman T, Zwang Y, Efroni S, Getz G, Straussman R. Predicting and affecting response to cancer therapy based on pathway-level biomarkers. *Nat Commun*. 2020 Jul 3;11(1):3296. PMID: 32620799; PMCID: PMC7335104.
5. Boldajipour B, Nelson A, Krummel MF. Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine. *JCI Insight*. 2016 Dec 8;1(20):e89289. PMID: 27942588; PMCID: PMC5135268.

6. Campbell JR, McDonald BR, Mesko PB, Siemers NO, Singh PB, Selby M, Sproul TW, Korman AJ, Vlach LM, Houser J, Sambanthamoorthy S, Lu K, Hatcher SV, Lohre J, Jain R, Lan RY. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models. *Cancer Res.* 2021 Jun 1;81(11):2983-2994. Epub 2021 Mar 23. PMID: 33757978.
7. Deshet-Unger N, Horn G, Rawet-Slobodkin M, Waks T, Laskov I, Michaan N, Raz Y, Bar V, Zundelevich A, Aharon S, Turovsky L, Mallel G, Salpeter S, Neev G, Hollander KS, Katz BZ, Grisaru D, Globerson Levin A. Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. *Biomedicines.* 2022 Sep 7;10(9):2216. PMID: 36140319; PMCID: PMC9496506.
8. Donelan W, Crispen PL, Kusmartsev S. Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma. *Methods Mol Biol.* 2023;2684:167-175. PMID: 37410234.
9. Farias A, Soto A, Puttur F, Goldin CJ, Sosa S, Gil C, Goldbaum FA, Berguer PM. A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment. *Sci Rep.* 2021 Jul 28;11(1):15406. PMID: 34321536; PMCID: PMC8319313.
10. Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Posada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, Chen IX, Naxerova K, Ng C, Westermarck AM, Duquette M, Roberge S, Lindeman NI, Lyssiotis CA, Nielsen J, Housman DE, Duda DG, Brachtel E, Golub TR, Cantley LC, Asara JM, Davidson SM, Fukumura D, Dartois VA, Clish CB, Jain RK, Vander Heiden MG. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. *Nat Cancer.* 2021 Apr;2(4):414-428. Epub 2021 Apr 1. Erratum in: *Nat Cancer.* 2021 Nov;2(11):1243. PMID: 34179825; PMCID: PMC8223728.
11. Gavert N, Zwang Y, Weiser R, Greenberg O, Halperin S, Jacobi O, Mallel G, Sandler O, Berger AJ, Stossel E, Rotin D, Grinshpun A, Kamer I, Bar J, Pines G, Saidian D, Bar I, Golan S, Rosenbaum E, Nadu A, Ben-Ami E, Weitzen R, Nechushtan H, Golan T, Brenner B, Nissan A, Margalit O, Hershkovitz D, Lahat G, Straussman R. Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer. *Nat Cancer.* 2022 Feb;3(2):219-231. Epub 2022 Feb 10. PMID: 35145327.
12. Greier MDC, Runge A, Dudas J, Carpentari L, Schartinger VH, Randhawa A, Mayr M, Petersson M, Riechelmann H. Optimizing culturing conditions in patient derived 3D primary slice cultures of head and neck cancer. *Front Oncol.* 2023 Mar 30;13:1145817. PMID: 37064104; PMCID: PMC10101142.
13. Hu KH, Eichorst JP, McGinnis CS, Patterson DM, Chow ED, Kersten K, Jameson SC, Gartner ZJ, Rao AA, Krummel MF. ZipSeq: barcoding for real-time mapping of single cell transcriptomes. *Nat Methods.* 2020 Aug;17(8):833-843. Epub 2020 Jul 6. PMID: 32632238; PMCID: PMC7891292.

14. Jacob Berger A, Gigi E, Kupersmidt L, Meir Z, Gavert N, Zwang Y, Prior A, Gilad S, Harush U, Haviv I, Stemmer SM, Blum G, Merquiol E, Mardamshina M, Kaminski Strauss S, Friedlander G, Bar J, Kamer I, Reizel Y, Geiger T, Pilpel Y, Levin Y, Tanay A, Barzel B, Reuveni H, Straussman R. IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy. *Nat Cancer*. 2021 Oct;2(10):1055-1070. Epub 2021 Oct 21. PMID: 35121883.
15. Kaneko K, Osada T, Morse MA, Gwin WR, Ginzel JD, Snyder JC, Yang XY, Liu CX, Diniz MA, Bodoor K, Hughes PF, Haystead TA, Lyerly HK. Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. *Commun Biol*. 2020 May 8;3(1):226. PMID: 32385408; PMCID: PMC7210113.
16. Kerr SC, Morgan MM, Gillette AA, Livingston MK, Lugo-Cintron KM, Favreau PF, Florek L, Johnson BP, Lang JM, Skala MC, Beebe DJ. A bioengineered organotypic prostate model for the study of tumor microenvironment-induced immune cell activation. *Integr Biol (Camb)*. 2020 Oct 16;12(10):250-262. PMID: 33034643; PMCID: PMC7569006.
17. Kersten K, Hu KH, Combes AJ, Samad B, Harwin T, Ray A, Rao AA, Cai E, Marchuk K, Artichoker J, Courau T, Shi Q, Belk J, Satpathy AT, Krummel MF. Spatiotemporal co-dependency between macrophages and exhausted CD8<sup>+</sup> T cells in cancer. *Cancer Cell*. 2022 Jun 13;40(6):624-638.e9. Epub 2022 May 26. PMID: 35623342; PMCID: PMC9197962.
18. Morgan MM, Livingston MK, Warrick JW, Stanek EM, Alarid ET, Beebe DJ, Johnson BP. Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model. *Sci Rep*. 2018 May 8;8(1):7139. PMID: 29740030; PMCID: PMC5940820.
19. Nia HT, Liu H, Seano G, Datta M, Jones D, Rahbari N, Incio J, Chauhan VP, Jung K, Martin JD, Askoxylakis V, Padera TP, Fukumura D, Boucher Y, Hornicek FJ, Grodzinsky AJ, Baish JW, Munn LL, Jain RK. Solid stress and elastic energy as measures of tumour mechanopathology. *Nat Biomed Eng*. 2016;1:0004. doi: 10.1038/s41551-016-0004. Epub 2016 Nov 28. PMID: 28966873; PMCID: PMC5621647.
20. Nia HT, Datta M, Seano G, Huang P, Munn LL, Jain RK. Quantifying solid stress and elastic energy from excised or in situ tumors. *Nat Protoc*. 2018 May;13(5):1091-1105. doi: 10.1038/nprot.2018.020. Epub 2018 Apr 19. PMID: 29674756; PMCID: PMC6546092.
21. Nickl V, Eck J, Goedert N, Hübner J, Nerreter T, Hagemann C, Ernestus RI, Schulz T, Nickl RC, Keßler AF, Löhr M, Rosenwald A, Breun M, Monoranu CM. Characterization and Optimization of the Tumor Microenvironment in Patient- Derived Organotypic Slices and Organoid Models of Glioblastoma. *Cancers (Basel)*. 2023 May 10;15(10):2698. doi: 10.3390/cancers15102698. PMID: 37345035; PMCID: PMC10216617.

22. O'Connor RA, Chauhan V, Mathieson L, Titmarsh H, Koppensteiner L, Young I, Tagliavini G, Dorward DA, Prost S, Dhaliwal K, Wallace WA, Akram AR. T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer. *Oncoimmunology*. 2021 Jul 8;10(1):1940675. doi: 10.1080/2162402X.2021.1940675. PMID: 34290905; PMCID: PMC8274440.
23. Park TI, Smyth LCD, Aalderink M, Woolf ZR, Rustenhoven J, Lee K, Jansson D, Smith A, Feng S, Correia J, Heppner P, Schweder P, Mee E, Dragunow M. Routine culture and study of adult human brain cells from neurosurgical specimens. *Nat Protoc*. 2022 Feb;17(2):190-221. doi: 10.1038/s41596-021-00637-8. Epub 2022 Jan 12. PMID: 35022619.
24. Riad A, Gitto SB, Lee H, Winters HD, Martorano PM, Hsieh CJ, Xu K, Omran DK, Powell DJ Jr, Mach RH, Makvandi M. PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response. *Molecules*. 2020 Dec 19;25(24):6029. doi: 10.3390/molecules25246029. PMID: 33352773; PMCID: PMC7766161.
25. Seibel AJ, Kelly OM, Dance YW, Nelson CM, Tien J. Role of Lymphatic Endothelium in Vascular Escape of Engineered Human Breast Microtumors. *Cell Mol Bioeng*. 2022 Nov 7;15(6):553-569. doi: 10.1007/s12195-022-00745-9. PMID: 36531861; PMCID: PMC9751254.
26. Stossel C, Raitses-Gurevich M, Atias D, Beller T, Glick Gorman Y, Halperin S, Peer E, Denroche RE, Zhang A, Notta F, Wilson JM, O'Kane GM, Haimov Talmoud E, Amison N, Schvimer M, Salpeter SJ, Bar V, Zundeleovich A, Tirosh I, Tal R, Dinstag G, Kinar Y, Eliezer Y, Ben-David U, Gavert NS, Straussman R, Gallinger SJ, Berger R, Golan T. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting. *Cancer Discov*. 2023 Aug 4;13(8):1826-1843. doi: 10.1158/2159-8290.CD-22-0412. PMID: 37449843; PMCID: PMC10401074.
27. Wu KZ, Adine C, Mitriashkin A, Aw BJJ, Iyer NG, Fong ELS. Making In Vitro Tumor Models Whole Again. *Adv Healthc Mater*. 2023 Jun;12(14):e2202279. doi: 10.1002/adhm.202202279. Epub 2023 Feb 22. PMID: 36718949.